TREATMENT OF LOCALIZED PROSTATE CANCER BY HIGH INTENSITY FOCUSED ULTRASOUND (HIFU); RESULTS OF THE FIRST FRENCH PROSPECTIVE STUDY ON PATIENTS NOT PREVIOUSLY TREATED: MINIMUM OF FIVE YEARS OF FOLLOW- UP

2008 ◽  
Vol 179 (4S) ◽  
pp. 496-496
Author(s):  
Pierre Conort ◽  
Pascal Rischmann ◽  
Henri Bensadoun ◽  
Daniel Chevallier ◽  
Christian Pfister ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prospective Study ◽  
High Intensity ◽  
Focused Ultrasound ◽  
High Intensity Focused Ultrasound ◽  
Localized Prostate Cancer ◽  
Previously Treated

scholarly journals High Intensity Focused Ultrasound versus Brachytherapy for the Treatment of Localized Prostate Cancer: A Matched-Pair Analysis

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Fouad Aoun ◽  
Ksenija Limani ◽  
Alexandre Peltier ◽  
Quentin Marcelis ◽  
Marc Zanaty ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Cox Regression ◽  
High Intensity Focused Ultrasound ◽  
Localized Prostate Cancer ◽  
Matched Pair ◽  
Significant Difference

Purpose. To evaluate postoperative morbidity and long term oncologic and functional outcomes of high intensity focused ultrasound (HIFU) compared to brachytherapy for the treatment of localized prostate cancer.Material and Methods. Patients treated by brachytherapy were matched 1 : 1 with patients who underwent HIFU. Differences in postoperative complications across the two groups were assessed using Wilcoxon’s rank-sum orχ2test. Kaplan-Meier curves, log-rank tests, and Cox regression models were constructed to assess differences in survival rates between the two groups.Results. Brachytherapy was significantly associated with lower voiding LUTS and less frequent acute urinary retention (p<0.05). Median oncologic follow-up was 83 months (13–123 months) in the HIFU cohort and 44 months (13–89 months) in the brachytherapy cohort. Median time to achieve PSA nadir was statistically shorter in the HIFU. Biochemical recurrence-free survival rate was significantly higher in the brachytherapy cohort compared to HIFU cohort (68.5% versus 53%,p<0.05). No statistically significant difference in metastasis-free, cancer specific, and overall survivals was observed between the two groups.Conclusion. HIFU and brachytherapy are safe with no significant difference in cancer specific survival on long term oncologic follow-up. Nonetheless, a randomized controlled trial is needed to confirm these results.

Sign in / Sign up

Export Citation Format

Share Document